Insider Trading & Ownership of Sharon Shacham

Location
Tel Aviv Yafo
Summary
The estimated net worth of Sharon Shacham is at least $1,383,966 dollars as of 20 May 2026. Sharon Shacham is the Chief Scientific Officer of Karyopharm Therapeutics Inc. and owns shares of Karyopharm Therapeutics Inc. (KPTI) stock worth about $1.37M. Sharon Shacham is the Director of Acrivon Therapeutics, Inc. and owns shares of Acrivon Therapeutics, Inc. (ACRV) stock worth about $13K.
Signature
/s/ Adam D. Levy, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Sharon Shacham and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Key facts

  • Sharon Shacham has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $1,383,966.
  • Recent insider filing activity is available below.

Change

  • Largest disclosed position: Karyopharm Therapeutics Inc. ($1,370,948).
  • Past-year value change for that position: .

Research use

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Sharon Shacham

NSRX Forms 3/4/5

Nasus Pharma Ltd

Relationship
Director
Holdings value
Past year net change
Change %
Report period
18 Mar 2026

Insider Transactions Reported by Sharon Shacham:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .